Cell BioEngines

CBE-201 Clin0 head & neck cancer, colorectal cancer; CBE-301 Clin0 multiple myeloma; CBE-401 Clin0 thrombocytopenia

Cell BioEngines is dedicated to developing a broad range of “off-the-shelf” cell therapies for treating cancer. Using their human Stem-SPACE platform, Cell BioEngines can perform large-scale differentiation of rare immune cells. They were established in 2022, founded by Ajay Vishwakarma, a Harvard-MIT trained scientist. He founded the company based on his PhD work, using single-cell next-generation RNA sequencing to identify unique immune cell types in tumors.

Jobs: